MEDCL.PA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

Loading chart

Pay with

ME

Mkt Cap

N/A

Volume

114.44K

Next Earnings

N/A

Chart Earnings News About Insider Filings

MedinCell (ENXTPA:MEDCL) Stock Could Be Overvalued On FDA Approval NewsMedinCell has seen its share price move sharply in recent years, and the latest headlines around its U.S. product launch plans put fresh attention on whether today's valuation is still grounded in the revenue it generates. With the stock now in focus again, the key issue is how i…finance.yahoo.com · Oct 13, 2026

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)MONTPELLIER, France, October 09, 2026--(BUSINESS WIRE)--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts. Webcast Details A replay of the webcast will be available on …finance.yahoo.com · Oct 9, 2026

Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026New Phase 3 analyses of Olanzapine LAI, currently under regulatory review, provided further insights into stabilization, long-term efficacy and treatment-switching strategies Additional real-world data reinforced UZEDY's clinical and economic benefits in the management of schizop…finance.yahoo.com · Sep 21, 2026

Medincell to Participate in Upcoming Investor ConferencesMONTPELLIER, France, September 09, 2026--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation in the following Sept…finance.yahoo.com · Sep 9, 2026

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 OutlookMONTPELLIER, France, July 29, 2026--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue…finance.yahoo.com · Jul 29, 2026

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 OutlookMONTPELLIER, France, July 29, 2026--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 20…finance.yahoo.com · Jul 29, 2026

Medincell Reports FY 2025-26 Annual ResultsA year marked by solid execution, with Continued UZEDY® ramp-up, supporting royalty growth Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva1 The first AbbVie program progressing toward the initiation of clinical development The …finance.yahoo.com · Jun 16, 2026

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsTeva Pharmaceutical Industries Ltd The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1administered every four weeks. If approved, TEV-‘749 could help fill a significant unmet need in available schizophr…finance.yahoo.com · May 21, 2026

Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑YearMONTPELLIER, France, April 29, 2026--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a 62% increase from $39 million in …finance.yahoo.com · Apr 29, 2026

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in AdultsOlanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment optionsby addressing …finance.yahoo.com · Feb 20, 2026

to start trading

ME

MEDCL.PAMEDCL.PA

MEDCL.PA

Pay with—

Available Balance0.00

Your PositionYou don't own any MEDCL.PA yet.

Related Tickers

Earnings